Skip to main content

A discussion by Safir Anand on the laws and codes of practices governing advertising of medicinal products in India.

In India, pharmaceutical advertising is governed by The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and The Drugs and Cosmetics Rules, 1945. However these Acts do not lay down the minimum essential information requirements for advertisements. The Organization of Pharmaceutical Producers of India in its Code of Pharmaceutical Marketing Practices also provide guidelines for the information requirements in advertisements and the allowed practices for the promotion of pharmaceutical products. The Indian department of Pharmaceuticals has also come up with a Code of Marketing Practice for Indian Pharmaceutical Industry which is a voluntary code of Marketing Practices for Indian Pharmaceutical Industry.

This chapter was published in ICLG’s Pharmaceutical Advertising 2013.

To continue reading, please contact us at email@anandandanand.com

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Jun 16, 2026

First published by Lexology. Authors: Pravin Anand and Dr. Neeti Wilson Introduction India’s biodiversity is one of its greatest strategic assets.

India’s Biodiversity Framework at a Crossroads: Industry Perspectives on the Biological Diversity Act and ABS Regulations, 2025
News & Updates, Thought Leadership
Jun 16, 2026

First published by Lexology. Authors: Sandhya Singh and Sampada Kapoor Introduction In today’s marketplace, consumers often identify products not

Protecting Colour as a Brand Asset: Lessons from the Exide-Amara Raja Decision
News & Updates, Thought Leadership
Jun 11, 2026

‘First published on Legal500’ By: Lakshmidevi Somanath The Supreme Court of India’s 2025 decision in K. Mangayarkarasi and Anr v. N. J. Sundaresan marks

Arbitrating Trademark Disputes Following Mangayarkarasi – The Extent of Contractual Reach into Public Law
Thought Leadership
May 30, 2026

‘First published on Enterprise IT World’ Author: Subroto Kumar Panda The defining question for every board of directors has changed. It is no longer,

From Blueprint to Battle-Ready: The CIO’s Executive Guide to Cyber Resilience